Australia
-
Australian pharmaceuticals market: Top growth opportunities
Despite Australia being a mature market for pharmaceuticals, there will be steady growth in coming years due to easy public access to its well-managed healthcare system.
Australia | 01 May 2011
-
Constant innovation in Australian biotech
Dr Bornadata (Bonnie) Bain, global director of healthcare research and analysis, Datamonitor comments: “Pharma’s continued need to restock pipelines in order to secure future growth—in the face of ongoing patent expiries—maintains ongoi…
Australia | 09 November 2010
-
Biosimilars in Australia: Nivestim
Expert comment from Lisette Oversteegen, lead analyst, Datamonitor . Compared with Europe, where several biosimilar products of three different molecules (epoetin, filgrastim and somatropin) have been approved since 2006, Australia’s biosimilars…
Australia | 22 October 2010
-
Australia considers Victoza for reimbursement
Expert comment from Lisette Oversteegen, lead analyst, Datamonitor : “In its November meeting, the Pharmaceutical Benefits Advisory Committee (PBAC) will consider Novo Nordisk's second-to-market glucagon-like peptide-1 (GLP-1) agonist Victoza f…
Australia | 21 October 2010
-
Cladribine tablets approved in Australia
The Australian Therapeutic Goods Administration (TGA) has approved Merck ’s Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis (MS). Cladribine tablets will be registered in Australia under the trade name Movectro. â…
Australia | 24 September 2010
-
Optimism over Australia election
Lisette Oversteegen, lead analyst from Datamonitor , comments on the impact of Australia’ election. Now that the Labor party has claimed a narrow victory, the pharmaceutical industry has reason to be optimistic about the Memorandum of Understand…
Australia | 22 September 2010
-
Overview of the Australian opioid market
There is an increase in prescription opioid use in recent years for both chronic and acute pain.
Australia | 01 September 2010
-
Hunter Immunology Seeks Funding for Clinical Trial
Australia-based biotechnology company Hunter Immunology is seeking to raise $8-10 million to fund a Phase IIb clinical trial of its lead product HI-164OV. The capital raising is cornerstoned by the IB Australian Bioscience Fund which has already …
Australia | 23 April 2010
-
Australia Increases Research Collaboration with China
A study from Thomson Reuters shows broadening international collaboration in the research of Australia and, to a lesser degree, New Zealand, over the past 10 years. The US continues to be the biggest contributor to Australian and New Zealand publicat…
Australia | 07 April 2010
-
Clinuvel to Commence US Patient Trials
An Australian drug to protect patients who are intolerant of light and sunlight will begin trials in the US. The US Food and Drug Administration (FDA) has given clearance to Melbourne’s Clinuvel Pharmaceuticals to commence a Phase II study (CUV030)…
Australia | 07 April 2010
